Anti-cancer effect of liriodenine on human lung cancer cells

Kaohsiung Journal of Medical Sciences

Volumn 20, Issue 8, 2004, Pages 365-371

  Chang, Hui Chiu ^a   Chang, Fang Rong ^a   Wu, Yang Chang ^a   Lai, Yung Hsiung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cyclin; Cyclin dependent kinase; Liriodenine; Poly(ADP ribose) polymerase

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYTOTOXIC AGENT; ISOQUINOLINE ALKALOID; LIPOCORTIN 5; LIRIODENINE; PROPIDIUM IODIDE; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; WESTERN BLOTTING;

EID: 4644241028     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70172-x     Document Type: Article

References (32)

1. Warthen D, Gooden EL, Jacobson M. Tumor inhibitors: liriodenine, a cytotoxic alkaloid from Annona glabra. J Pharm Sci 1969;58:637-8.
2. Chen KS, Ko FN, Teng CM, et al. Anti-platelet and vasorelaxing actions of some aporpinoids. Planta Med 1996;62:133-6.
3. Clark AM, Watson ES, Ashfaq MK, et al. In vivo efficacy of anti-fungal oxoaporphine alkaloids in experimental disseminated candidiasis. Pharm Res 1987;4:495-8.
4. Hufford CD, Funderburk MJ, Morgan JM, et al. Two antimicrobial alkaloids from heartwood of Liriodendron tulipifera L. J Pharm Sci 1975;64:789-92.
5. Chang GJ, Wu MH, Wu YC, et al. Electrophysiological mechanisms for anti-arrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from Fissistigma glaucescens. Br J Pharmacol 1996;118:1571-83.
6. Lin CH, Chang GJ, Su MJ, et al. Pharmacological characteristics of liriodenine, isolated from Fissistigma glaucescens, a novel muscarinic receptor antagonist in guinea-pigs. Br J Pharmacol 1994;113:275-81.
7. Woo SH, Reynolds MC, Sun NJ, et al. Inhibition of topoisomerase II by liriodenine. Biochem Pharmacol 1997;54:467-73.
8. Woo SH, Sun NJ, Cassady JM, et al. Topoisomerase II inhibition by aporphine alkaloids. Biochem Pharmacol 1999;57:1141-5.
9. Wu YC, Yamagishi T, Lee KH. Cytotoxic isoquinoline alkaloids from Xanthorhiza simplicissima. Kaohsiung J Med Sci 1989;5:409-11.
10. Hunter T, Pines P. Cyclins and cancer. Cell 1991;66:1071-4.
11. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
12. Pines J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci 1993;18:195-7.
13. Schuuring E, Verhoeven E, Mooi WJ, et al. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992;7:355-61.
14. Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-3.
15. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-5.
16. Matsushime H, Ewen ME, Strom DK, et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992;71:323-34.
17. Kitahara K, Yasui W, Kuniyasu H, et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995;62:25-8.
18. Reifenberger G, Reifenberger J, Ichimura K, et al. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994;54:4299-303.
19. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050-4.
20. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
21. Lu ST, Wu YC, Leou SP. Alkaloids of Formosan Fissistigma and Goniothalamus species. Phytochemistry 1985;24:1829-34.
22. Chang HC, Tsai LH, Chuang LY, et al. Role of AKT kinase in sphingosine-induced apoptosis in human hepatoma cells. J Cell Physiol 2001;188:188-93.
23. Hung WC, Chang HC, Chuang LY. Transforming growth factor beta 1 potently activates CPP32-like proteases in human hepatoma cells. Cell Signal 1998;10:511-5.
24. Lee TH, Chuang LY, Hung WC. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene 1999;18:4269-74.
25. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-16.
26. Smits VA, Medema RH. Checking out the G2/M transition. Biochim Biophys Acta 2001;1519:1-12.
27. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4.
28. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 1991;10:3321-9.
29. Xiao D, Srivastava SK, Lew KL, et al. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis 2003;24:891-7.
30. Tyagi AK, Singh RP, Agarwal C, et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002;8:3512-9.
31. Tseng CJ, Wang WJ, Liang YC, et al. Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells. Toxicology 2002;175:123-42.
32. Huang TS, Shu CH, Chao Y, et al. Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 2000;5:235-41.